Inclusion Criteria

Inclusion Criteria

- Subject completed a romiplostim study for the treatment of thrombocytopenia in
subjects with MDS

- Subject has an Eastern Cooperative Oncology (ECOG) performance status of 0 to 2

- Subject had a platelet count ≤ 50 x 10^9/L since the final dose of investigational
product in the parent study

- Subject or his/her legally acceptable representative provided written informed
consent before any study-specific procedures were initiated

Exclusion Criteria

- Subject has been diagnosed with AML or has a blast count ≥ 10% by peripheral blood or
bone marrow biopsy

- Subject has a prior history of leukemia

- Subject has a prior history of bone marrow or stem cell transplantation

- Subject has a prior malignancy (other than in situ cervical cancer, controlled
prostate cancer, or basal cell cancer of the skin) unless treated with curative
intent and without evidence of disease for ≥ 3 years before randomization

- Subject has active or uncontrolled infections

- Subject has unstable angina, congestive heart failure [New York Heart Association
(NYHA) > class II], uncontrolled hypertension (diastolic > 100 mmHg), uncontrolled
cardiac arrhythmia, or recent (within 1 year) myocardial infarction

- Subject has a history of arterial thrombosis (eg, stroke or transient ischemic
attack) in the past year

- Subject has a history of venous thrombosis that currently requires anti-coagulation
therapy

- Subject received interleukin (IL)-11 within 4 weeks of screening

- Subject previously received a thrombopoietic growth factor (other than romiplostim)

- Subject has a known hypersensitivity to any recombinant E coli-derived product (eg,
Infergen®, Neupogen®, Somatropin, Actimmune)

- Subject is currently enrolled in investigational device or drug study(ies), has not
yet completed at least 4 weeks since ending investigational device or drug study(ies)
(other than parent romiplostim study), or subject is receiving other investigational
agent(s)/device(s)

- Subject is of child-bearing potential and is evidently pregnant (eg, positive human
chorionic gonadotropin [HCG] test) or is breast feeding

- Subject is not using adequate contraceptive precautions

- Subject has any kind of disorder that compromises his/her ability to give written
informed consent (and does not have a legally acceptable representative) or is unable
to comply with study procedures